Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299305 | 0.90 | HTR4 (0.55) | HTR4LMNANPY1RNPY2R | |
| SCHEMBL2334767 | 0.89 | HTR4 (0.60) | HTR4 | |
| SCHEMBL2335311 | 0.88 | LMNA (0.52) | LMNANPY1RNPY2RMEN1KMT2A | |
| SCHEMBL2333122 | 0.88 | HTR4 (0.54) | HTR4LMNANPY1RNPY2R | |
| SCHEMBL2336956 | 0.88 | HTR4 (0.57) | HTR4 | |
| SCHEMBL2335431 | 0.87 | HTR4 (0.58) | HTR4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3299088 | 0.86 | HTR4 (0.57) | HTR4ALDH1A1 | |
| SCHEMBL2340631 | 0.86 | HTR4 (0.57) | HTR4KMT2A | |
| SCHEMBL3299419 | 0.85 | HTR4 (0.55) | HTR4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3333373 | 0.84 | HTR4 (0.53) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | claimed |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-15 | — | — | US | claimed |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-12-04 | — | — | US | disclosed |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-09-28 | — | — | US | disclosed |
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-12-15 | — | — | US | disclosed |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-15 | — | — | US | disclosed |
| US-8642772-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-02-04 | — | — | US | disclosed |
| EP-2358702-B1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-07-17 | — | — | EP | disclosed |
| EP-2358702-A2 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK Holdings Co., Ltd. (KR) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010044585-A2 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK HOLDINGS CO., LTD. (KR) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK HOLDINGS CO., LTD. (KR) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885LMNA 2761/4885NPY1R 3176/4885 |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | PGC, VIP, PIGO | HTR4 308/4885LMNA 2761/4885NPY1R 3176/4885 |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | PGC, VIP, PIGO | HTR4 308/4885LMNA 2761/4885NPY1R 3176/4885 |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885LMNA 2761/4885NPY1R 3176/4885 |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885LMNA 2761/4885NPY1R 3176/4885 |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885LMNA 2761/4885NPY1R 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.